FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896783905> ?p ?o ?g. }

• W2896783905 endingPage "80" @default.
• W2896783905 startingPage "70" @default.
• W2896783905 abstract "Abstract Inhibition of the B-cell receptor (BCR) signaling pathway is a promising treatment strategy in multiple B-cell malignancies. However, the role of BCR blockade in diffuse large B-cell lymphoma (DLBCL) remains undefined. We recently characterized primary DLBCL subsets with distinct genetic bases for perturbed BCR/phosphoinositide 3-kinase (PI3K) signaling and dysregulated B-cell lymphoma 2 (BCL-2) expression. Herein, we explore the activity of PI3K inhibitors and BCL-2 blockade in a panel of functionally and genetically characterized DLBCL cell line models. A PI3K inhibitor with predominant α/δ activity, copanlisib, exhibited the highest cytotoxicity in all BCR-dependent DLBCLs. The proapoptotic effect of copanlisib was associated with DLBCL subtype-specific dysregulated expression of BCL-2 family members including harakiri (HRK) and its antiapoptotic partner BCL extra large (BCL-xL), BCL2 related protein A1, myeloid cell leukemia 1 (MCL-1), and BCL2 interacting mediator of cell death. Using functional BH3 profiling, we found that the cytotoxic activity of copanlisib was primarily mediated through BCL-xL and MCL-1–dependent mechanisms that might complement BCL-2 blockade. For these reasons, we evaluated single-agent activity of venetoclax in the DLBCLs and identified a subset with limited sensitivity to BCL-2 blockade despite having genetic bases of BCL-2 dysregulation. As these were largely BCR-dependent DLBCLs, we hypothesized that combined inhibition of PI3Kα/δ and BCL-2 would perturb BCR-dependent and BCL-2–mediated survival pathways. Indeed, we observed synergistic activity of copanlisib/venetoclax in BCR-dependent DLBCLs with genetic bases for BCL-2 dysregulation in vitro and confirmed these findings in a xenograft model. These results provide preclinical evidence for the rational combination of PI3Kα/δ and BCL-2 blockade in genetically defined DLBCLs." @default.
• W2896783905 created "2018-10-26" @default.
• W2896783905 creator A5020614289 @default.
• W2896783905 creator A5021363179 @default.
• W2896783905 creator A5022857112 @default.
• W2896783905 creator A5029765553 @default.
• W2896783905 creator A5031010918 @default.
• W2896783905 creator A5031962066 @default.
• W2896783905 creator A5055160574 @default.
• W2896783905 creator A5057707744 @default.
• W2896783905 creator A5073588292 @default.
• W2896783905 creator A5074215180 @default.
• W2896783905 creator A5087362622 @default.
• W2896783905 date "2019-01-03" @default.
• W2896783905 modified "2023-10-16" @default.
• W2896783905 title "Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL" @default.
• W2896783905 cites W1976564639 @default.
• W2896783905 cites W1979816280 @default.
• W2896783905 cites W2002395443 @default.
• W2896783905 cites W2007886976 @default.
• W2896783905 cites W2031885687 @default.
• W2896783905 cites W2061621597 @default.
• W2896783905 cites W2065942364 @default.
• W2896783905 cites W2066404900 @default.
• W2896783905 cites W2083470652 @default.
• W2896783905 cites W2085187495 @default.
• W2896783905 cites W2087693130 @default.
• W2896783905 cites W2096439168 @default.
• W2896783905 cites W2116177527 @default.
• W2896783905 cites W2121510983 @default.
• W2896783905 cites W2125640515 @default.
• W2896783905 cites W2136426653 @default.
• W2896783905 cites W2165056381 @default.
• W2896783905 cites W2166188515 @default.
• W2896783905 cites W2169450835 @default.
• W2896783905 cites W2172242534 @default.
• W2896783905 cites W2280585894 @default.
• W2896783905 cites W2290466312 @default.
• W2896783905 cites W2339774970 @default.
• W2896783905 cites W2555761459 @default.
• W2896783905 cites W2571275916 @default.
• W2896783905 cites W2582696216 @default.
• W2896783905 cites W2756389342 @default.
• W2896783905 cites W2760227417 @default.
• W2896783905 cites W2766623255 @default.
• W2896783905 cites W2800133359 @default.
• W2896783905 cites W2801763724 @default.
• W2896783905 cites W885739806 @default.
• W2896783905 doi "https://doi.org/10.1182/blood-2018-08-872465" @default.
• W2896783905 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6318426" @default.
• W2896783905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30322870" @default.
• W2896783905 hasPublicationYear "2019" @default.
• W2896783905 type Work @default.
• W2896783905 sameAs 2896783905 @default.
• W2896783905 citedByCount "68" @default.
• W2896783905 countsByYear W28967839052019 @default.
• W2896783905 countsByYear W28967839052020 @default.
• W2896783905 countsByYear W28967839052021 @default.
• W2896783905 countsByYear W28967839052022 @default.
• W2896783905 countsByYear W28967839052023 @default.
• W2896783905 crossrefType "journal-article" @default.
• W2896783905 hasAuthorship W2896783905A5020614289 @default.
• W2896783905 hasAuthorship W2896783905A5021363179 @default.
• W2896783905 hasAuthorship W2896783905A5022857112 @default.
• W2896783905 hasAuthorship W2896783905A5029765553 @default.
• W2896783905 hasAuthorship W2896783905A5031010918 @default.
• W2896783905 hasAuthorship W2896783905A5031962066 @default.
• W2896783905 hasAuthorship W2896783905A5055160574 @default.
• W2896783905 hasAuthorship W2896783905A5057707744 @default.
• W2896783905 hasAuthorship W2896783905A5073588292 @default.
• W2896783905 hasAuthorship W2896783905A5074215180 @default.
• W2896783905 hasAuthorship W2896783905A5087362622 @default.
• W2896783905 hasBestOaLocation W28967839051 @default.
• W2896783905 hasConcept C170493617 @default.
• W2896783905 hasConcept C190283241 @default.
• W2896783905 hasConcept C203014093 @default.
• W2896783905 hasConcept C2777938653 @default.
• W2896783905 hasConcept C2778461978 @default.
• W2896783905 hasConcept C2778468042 @default.
• W2896783905 hasConcept C2779675984 @default.
• W2896783905 hasConcept C43907098 @default.
• W2896783905 hasConcept C502942594 @default.
• W2896783905 hasConcept C54355233 @default.
• W2896783905 hasConcept C86554907 @default.
• W2896783905 hasConcept C86803240 @default.
• W2896783905 hasConceptScore W2896783905C170493617 @default.
• W2896783905 hasConceptScore W2896783905C190283241 @default.
• W2896783905 hasConceptScore W2896783905C203014093 @default.
• W2896783905 hasConceptScore W2896783905C2777938653 @default.
• W2896783905 hasConceptScore W2896783905C2778461978 @default.
• W2896783905 hasConceptScore W2896783905C2778468042 @default.
• W2896783905 hasConceptScore W2896783905C2779675984 @default.
• W2896783905 hasConceptScore W2896783905C43907098 @default.
• W2896783905 hasConceptScore W2896783905C502942594 @default.
• W2896783905 hasConceptScore W2896783905C54355233 @default.
• W2896783905 hasConceptScore W2896783905C86554907 @default.
• W2896783905 hasConceptScore W2896783905C86803240 @default.
• W2896783905 hasIssue "1" @default.

• next